Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pf-04217903. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 20/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 2/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pf-04217903 SCHEMBL29394198 | 1.00 | MET (1.00) | METPDE3BPDE3ACYP2C9PDE10A | |
| Pf-04217903 SCHEMBL29355971 | 1.00 | MET (1.00) | METPDE3BPDE3ACYP2C9PDE10A | |
| Pf-04217903 SCHEMBL1178807 | 0.99 | MET (0.98) | METPDE3BPDE3ACYP2C9PDE10A | |
| Pf-04217903 SCHEMBL1178245 | 0.96 | MET (0.92) | METPDE3BPDE3ACYP2C9PDE10A | |
| Pf-04217903 SCHEMBL1178576 | 0.96 | MET (0.92) | METPDE3BPDE3ACYP2C9PDE10A | |
| Pf-04217903 SCHEMBL2571581 | 0.94 | MET (0.89) | METPDE3BPDE3ACYP2C9PDE10A | |
| Pf-04217903 SCHEMBL1180632 | 0.94 | MET (0.88) | METPDE3BPDE3ACYP2C9PDE10A | |
| Pf-04217903 SCHEMBL1180629 | 0.94 | MET (0.88) | METPDE3BPDE3ACYP2C9PDE10A | |
| SCHEMBL2572767 | 0.91 | MET (0.84) | METPDE3BPDE3ACYP2C9PDE10A | |
| SCHEMBL2573354 | 0.90 | MET (1.00) | METPDE3BPDE3ACYP2C9PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463743-B2 | Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2019-11-05 | — | — | US | claimed |
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | claimed |
| EP-2018383-B1 | TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | PFIZER PROD INC (US) | 2011-11-09 | — | — | EP | claimed |
| US-7732604-B2 | Triazolopyrazine derivatives | PFIZER INC. (US) | 2010-06-08 | — | — | US | claimed |
| EP-2018383-A1 | TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | Pfizer Products Inc. (US) | 2009-01-28 | — | — | EP | claimed |
| WO-2007132308-A1 | TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | claimed |
| US-20070265272-A1 | TRIAZOLOPYRAZINE DERIVATIVES | PFIZER INC. | 2007-11-15 | — | — | US | claimed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| EP-4541381-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2026-02-04 | — | — | EP | disclosed |
| EP-4545101-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4545100-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4541380-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| US-12491272-B2 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2025-12-09 | — | — | US | disclosed |
| WO-2009068955-A2 | POLYMORPHS OF A C-MET/HGFR INHIBITOR | PFIZER INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| EP-2018383-A1 | TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | Pfizer Products Inc. (US) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007132308-A1 | TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132308-A1 | TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070265272-A1 | TRIAZOLOPYRAZINE DERIVATIVES | PFIZER INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070265272-A1 | TRIAZOLOPYRAZINE DERIVATIVES | PFIZER INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070265272-A1 | TRIAZOLOPYRAZINE DERIVATIVES | PFIZER INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265272-A1 | TRIAZOLOPYRAZINE DERIVATIVES | JAK2, ABL1, CCND2 | MET 2876/4885PDE3B 1010/4885PDE3A 838/4885 |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | MET 1078/4885PDE3B 4870/4885PDE3A 4727/4885 |
| US-12491272-B2 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | MET 2278/4885PDE3B 3032/4885PDE3A 2965/4885 |
| US-10463743-B2 | Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof | ABCB4, ABCB1, LCAT | MET 442/4885PDE3B 3922/4885PDE3A 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.